A Study of Surovatamig (AZD0486) Plus Rituximab in Previously Untreated Follicular Lymphoma Patients

This is a global, randomised, Phase III, multicentre, open-label study evaluating the efficacy, safety and the degree of added benefit of the Surovatamig (AZD0486) plus rituximab combination compared to Investigator's choice of 3 standard immunochemotherapy regimen, conducted in participants with untreated FL.

Trial Details

NCT ID
NCT06549595
Phase
PHASE3
Sponsor
AstraZeneca
Status
RECRUITING
Cancer Type
Non-Hodgkin Lymphoma Lymphoma
Interventions
  • Surovatamig
  • R-CHOP
  • R-CVP
  • BR
Locations (sample)
  • Huntsville, Alabama, United States|34.7304,-86.58594
  • Anchorage, Alaska, United States|61.21806,-149.90028
  • Phoenix, Arizona, United States|33.44838,-112.07404
  • Clovis, California, United States|36.82523,-119.70292
  • Los Alamitos, California, United States|33.80307,-118.07256

Key Eligibility Criteria

  • Participant must be at least 18 years of age, inclusive, at the time of signing the ICF.
  • Histologically confirmed diagnosis of classic FL per WHO 2022 classification
  • ECOG performance status of 0 to 2
  • No prior systemic lymphoma-directed therapy

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Non-Hodgkin Lymphoma Lymphoma Trials on Trialify →